q/barr/
| We're sorry, that page (http://www.bio-medicine.org/q/barr/) was not found. Search q barr at Google Search q barr at Yahoo Search q barr at Msn |
Breaking Biology Technology:New technology could boost disease detection tests' speed and sensitivity 2Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2
[0] New technology could boost disease detection tests' speed and sensitivity[0] Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology[0] EUCODIS Bioscience Appoints Thomas Fischer as New CEO
Breaking Medicine Technology:Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2Stater Bros Raises 24266 429 00 for the Leukemia 26 Lymphoma Society 54232 1Stater Bros Raises 24266 429 00 for the Leukemia 26 Lymphoma Society 54232 2Epix Pharmaceuticals Inc Announces PRX 07034 Therapeutics CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 54229 1Epix Pharmaceuticals Inc Announces PRX 07034 Therapeutics CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 54229 2The public overestimates benefits of cancer screening survey finds 54226 1
[0] Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture[0] Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy[0] Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market
| Copyright © 2003-2007 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |